drugset / Trial / NCT04543110
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
Phase 2
Unknown
16 enrolled
Ottawa Hospital Research Institute
AstraZeneca · collabCross Cancer Institute · collabHamilton Health Sciences Corporation · collabLondon Health Sciences Centre · collabOntario Institute for Cancer Research · collabOzmosis Research Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study assesses the effect of sequential radiation and durvalumab immunotherapy given as treatment prior to surgery with radical cystectomy for bladder cancer.
Timeline
- Start
- 2021-01-29
- Primary completion
- 2023-10
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |